![ISPOR Europe 2024 – May 5-8. Register now.]({"type":"image" , "src" : "/sda/112342/JournalAd-ISPOR-2024-Leaderboard.jpg"})
Citations (13)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Junwen Zhou, Aurélie Millier & Mondher Toumi. (2018) Systematic review of pharmacoeconomic models for schizophrenia. Journal of Market Access & Health Policy 6:1.
Read now
Read now
Thomas R. Einarson, Susana Maia-Lopes, Pushpendra Goswami, Basil G. Bereza & Kristel Van Impe. (2016) Economic analysis of paliperidone long-acting injectable for chronic schizophrenia in Portugal. Journal of Medical Economics 19:9, pages 913-921.
Read now
Read now
Daniel Resende Faleiros, Juliana Álvares, Alessandra Maciel Almeida, Vânia Eloisa de Araújo, Eli Iola Gurgel Andrade, Brian B. Godman, Francisco A. Acurcio & Augusto A. Guerra Júnior. (2016) Budget impact analysis of medicines: updated systematic review and implications. Expert Review of Pharmacoeconomics & Outcomes Research 16:2, pages 257-266.
Read now
Read now
Thomas R. Einarson, Hanna Pudas, Pushpendra Goswami, Kristel van Impe & Basil G. Bereza. (2016) Pharmacoeconomics of long-acting atypical antipsychotics for acutely relapsed chronic schizophrenia in Finland. Journal of Medical Economics 19:2, pages 121-130.
Read now
Read now
Birgitta von Schéele, Josephine Mauskopf, Thor-Henrik Brodtkorb, Claire Ainsworth, Carmen Galani Berardo & Anita Patel. (2014) Relationship between modeling technique and reported outcomes: case studies in models for the treatment of schizophrenia. Expert Review of Pharmacoeconomics & Outcomes Research 14:2, pages 235-257.
Read now
Read now
Pierre Chue & James Chue. (2012) The cost–effectiveness of risperidone long-acting injection in the treatment of schizophrenia. Expert Review of Pharmacoeconomics & Outcomes Research 12:3, pages 259-269.
Read now
Read now
Articles from other publishers (7)
Benjamin Kearns, Katy Cooper, Martin Orr, Munira Essat, Jean Hamilton & Anna Cantrell. (2022) The Incidence and Costs of Adverse Events Associated with Antidepressants: Results from a Systematic Review, Network Meta-Analysis and Multi-Country Economic Model. Neuropsychiatric Disease and Treatment Volume 18, pages 1133-1143.
Crossref
Crossref
Huajie Jin, Paul Tappenden, Stewart Robinson, Evanthia Achilla, James H. MacCabe, David Aceituno & Sarah Byford. (2020) A Systematic Review of Economic Models Across the Entire Schizophrenia Pathway. PharmacoEconomics 38:6, pages 537-555.
Crossref
Crossref
Simon Frey, Roland Linder, Georg Juckel & Tom Stargardt. (2013) Cost-effectiveness of long-acting injectable risperidone versus flupentixol decanoate in the treatment of schizophrenia: a Markov model parameterized using administrative data. The European Journal of Health Economics 15:2, pages 133-142.
Crossref
Crossref
Evanthia Achilla & Paul McCrone. (2013) The Cost Effectiveness of Long-Acting/Extended-Release Antipsychotics for the Treatment of Schizophrenia. Applied Health Economics and Health Policy 11:2, pages 95-106.
Crossref
Crossref
Ananth Kadambi, Robert J. Leipold, Anuraag R. Kansal, Sonja Sorensen & Denis Getsios. (2012) Inclusion of Compliance and Persistence in Economic Models. Applied Health Economics and Health Policy 10:6, pages 365-379.
Crossref
Crossref
Ananth Kadambi, Robert J. Leipold, Anuraag R. Kansal, Sonja Sorensen & Denis Getsios. (2012) Inclusion of Compliance and Persistence in Economic Models. Applied Health Economics and Health Policy 10:6, pages 365-379.
Crossref
Crossref
Ewa Orlewska & Laszlo Gulácsi. (2009) Budget-Impact Analyses. PharmacoEconomics 27:10, pages 807-827.
Crossref
Crossref